Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity

被引：11

作者：

Benucci, Maurizio ^{[1
]}

Grossi, Valentina ^{[2
]}

Manfredi, Mariangela ^{[2
]}

Damiani, Arianna ^{[1
]}

Infantino, Maria ^{[2
]}

Moscato, Paolo ^{[3
]}

Cinquanta, Luigi ^{[5
]}

Gremese, Elisa ^{[4
,6
]}

Tolusso, Barbara ^{[4
]}

Petricca, Luca ^{[4
]}

Fedele, Anna Laura ^{[4
]}

Alivernini, Stefano ^{[4
,6
]}

Atzeni, Fabiola ^{[7
]}

Minisola, Giovanni ^{[8
]}

Verna, Roberto ^{[9
,10
]}

机构：

[1] S Giovanni di Dio Hosp, Rheumatol Unit, Florence, Italy

[2] S Giovanni di Dio Hosp, Immunol & Allergol Lab Unit, Florence, Italy

[3] Univ Hosp San Giovanni di Dio & Ruggi dAragona, Dept Med, Salerno, Italy

[4] IRCCS, Fdn Policlin Univ A Gemelli, Div Rheumatol, Rome, Italy

[5] SDN SPA Synlab Lab, Salerno, Italy

[6] Univ Cattolica Sacro Cuore, Div Rheumatol, Rome, Italy

[7] Univ Messina, Rheumatol Unit, Messina, Italy

[8] Italian Soc Rheumatol, Milan, Italy

[9] World Assoc Soc Pathol & Lab Med, Milan, Italy

[10] Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy

来源：

ANNALS OF LABORATORY MEDICINE | 2020年 / 40卷 / 02期

关键词：

Anti-tumor necrosis factor (TNF) drugs; Antibodies; Anti-drug antibodies; Bio-logical drugs; LONG-TERM TREATMENT; CHRONIC INFLAMMATORY DISEASES; ANTI-INFLIXIMAB ANTIBODIES; POINT-OF-CARE; ARTHRITIS PATIENTS; ANKYLOSING-SPONDYLITIS; DOUBLE-BLIND; ADALIMUMAB ANTIBODIES; INNOVATOR INFLIXIMAB; TREATMENT FAILURE;

D O I：

10.3343/alm.2020.40.2.101

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.

引用

页码：101 / 113

页数：13

共 93 条

[1] Immunogenicity of anti-tumor necrosis factor antibodies - toward improved methods of anti-antibody measurement [J].

Aarden, Lucien ;

Ruuls, Sigrid R. ;

Wolbink, Gertjan .

CURRENT OPINION IN IMMUNOLOGY, 2008, 20 (04) :431-435

[2] Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point-of-care quantitative test with two established ELISA assays [J].

Afonso, J. ;

Lopes, S. ;

Goncalves, R. ;

Caldeira, P. ;

Lago, P. ;

Tavares de Sousa, H. ;

Ramos, J. ;

Goncalves, A. R. ;

Ministro, P. ;

Rosa, I. ;

Vieira, A. I. ;

Dias, C. C. ;

Magro, F. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (07) :684-692

[3] Therapeutic drug monitoring of CT-P13: a comparison of four different immunoassays [J].

Afonso, Joana ;

de Sousa, Helena Tavares ;

Rosa, Isadora ;

Carvalho, Joao ;

Dias, Claudia Camila ;

Magro, Fernando .

THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2017, 10 (09) :661-671

[4] Epidemiology and risk factors for IBD [J].

Ananthakrishnan, Ashwin N. .

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2015, 12 (04) :205-217

[5]

[Anonymous], 2010, EMACHMPBMWP862892010, P9

[6]

[Anonymous], 2014, Taking stock of the Europe 2020 strategy for smart, sustainable and inclusive growth, P1, DOI DOI 10.2802/20493

[7]

[Anonymous], 2020, AB AC ZYT

[8]

[Anonymous], EMEACHMPBMWP14327200, P7

[9] Assays for Infliximab Drug Levels and Antibodies: AMatter of Scales and Categories [J].

Bader, L. I. ;

Solberg, S. M. ;

Kaada, S. H. ;

Bolstad, N. ;

Warren, D. J. ;

Gavasso, S. ;

Gjesdal, C. G. ;

Vedeler, C. A. .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2017, 86 (03) :165-170

[10] Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study [J].

Bartelds, G. M. ;

Wijbrandts, C. A. ;

Nurmohamed, M. T. ;

Stapel, S. ;

Lems, W. F. ;

Aarden, L. ;

Dijkmans, B. A. C. ;

Tak, P. P. ;

Wolbink, G. J. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (05) :817-821

← 1 2 3 4 5 6 7 8 9 10 →